NCT02359929View on ClinicalTrials.gov

BMT Autologous MSCs for GvHD

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

June 15, 2020

Study Completion Date

January 11, 2021

Conditions
Graft Versus Host DiseaseAcute Graft Versus Host DiseaseChronic Graft Versus Host Disease
Interventions
BIOLOGICAL

Autologous mesenchymal stromal cells (MSCs)

Infusion of MSCs delivered to each patient will depend on their weight and assigned dose level. The maximal individual dose of MSCs any patient will receive is 2 x 1000000 cells/kg.

Trial Locations (1)

30322

Children's Healthcare of Atlanta/Emory University, Atlanta

All Listed Sponsors
collaborator

CURE Foundation

OTHER

lead

Emory University

OTHER

NCT02359929 - BMT Autologous MSCs for GvHD | Biotech Hunter | Biotech Hunter